BC Week In Review | Jun 30, 2008
Clinical News

Satraplatin: Phase II started

GPC began an open-label, U.S. Phase II trial to evaluate oral satraplatin in combination with prednisone in up to 66 patients previously treated with docetaxel. GPC licensed Orplatna from Spectrum in 2002, while Celgene has...
BC Week In Review | Jan 21, 2008
Company News

Genzyme, Moffitt Cancer Center deal

Genzyme Corp. (NASDAQ:GENZ), Cambridge, Mass.   Moffitt Cancer Center , Tampa, Fla.   Business: Pharmacogenetics   The center granted Genzyme exclusive, worldwide rights to develop and commercialize diagnostics that use two protein biomarkers to predict patient...
BC Extra | Feb 24, 2007
Clinical News

Researchers report NSCLC survival determinants

Researchers from the H. Lee Moffitt Cancer Center published in The New England Journal of Medicine that the proteins RRM1 and ERCC1 are determinants of survival after surgical treatment of early-stage, non-small cell lung cancer...
Items per page:
1 - 3 of 3